Navigation Links
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Date:3/8/2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement shrinking tumors in most patients and extending survival for several months patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma the most deadly form of skin cancer tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive m
'/>"/>

Contact: Michelle Marcella
mmarcella@partners.org
617-724-2755
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
2. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
3. Inhibitors of shuttle molecule show promise in acute leukemia
4. Leukemia inhibitory factor may be a promising target against pancreatic cancer
5. Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. New mechanism of action for PARP inhibitors discovered
9. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
10. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Written and narrated by award winning author Dr. James ... Happiest Man In the World: Life Lessons From a Cultural ... Project C.U.R.E. came to be. , Raised in the Boise ... Richard W. Jackson, Dr. Jackson exceeded his goal of being ... he wasn’t happy. Prompted by this realization, James and his ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Not only ... create products free of petroleum, parabens and other cancer-causing ... that fund research, education and awareness programs that help ... staff and owners have raised an incredible, record-breaking contribution ... the Cure, sales of the Sweet Red Rose Whip ...
(Date:11/28/2014)... Hamilton, ON Canada (PRWEB) November 28, 2014 ... labels for the stuff kids lose® and an award-winning ... Julie Cole, Julie Ellis, Cynthia Esp, and Tricia Mumby ... Entrepreneur Award. They were recognized with the PROFIT Award ... Cole, Julie Ellis, Cynthia Esp, and Tricia Mumby) accepted ...
(Date:11/28/2014)... Lice Troopers Lice Removal Service is pleased to ... lice service for moms in Miami-Dade County. Lice Troopers is ... on Pone De-leon Blvd in Miami. The company currently ... Miami-Dade & Broward. Lice Troopers is the only Lice Clinic ... been treating families for several years. , Lice Troopers estimate ...
(Date:11/28/2014)... Schools like Centra Rivermont understand the therapeutic ... equipment to its students. That is why the ... play structure at its mental health services facility ... programs for children who are identified as needing ... have served the needs of children with severe ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... , NEW YORK, July 21 BET News correspondent, Andre ... Obama,s news conference in Washington on Wednesday, July 22 ( ... BET J will re-air an encore broadcast of the entire news conference ... Sophia Nelson at 10:00 p.m. The President is expected ...
... KALAMAZOO, Mich., July 21 Stryker Corporation (NYSE: SYK ) reported ... , Second Quarter Highlights , ... million were flat (0.1% decrease) on a constant currency basis (4.6% decrease as ... constant currency basis (0.2% decrease as reported) , MedSurg ...
... , , ALISO VIEJO, Calif., July 21 ... it will host a conference call and a live Internet webcast along ... EDT (7:00 a.m. PDT) to discuss results for the 2009 second quarter. ... on this call is (877) 295-5743, confirmation code 20797641. International callers ...
... MEQUON, Wis., July 21 Wonderbox Technologies has released version ... from continued advances in technology and software features. Central to ... managed care benefit administration and case management. The Care Management ... and monitoring day-to-day care tasks and case assignments. , ...
... , , NEW YORK, July ... action against MetLife. The class action involves MetLife,s April 2000 conversion ... class action certified by the Federal Court in New York includes ... , The notice of the class action ...
... on how they help arteries stay clear and healthy , ... technology, researchers have begun to discover the exact molecular reasons ... -- and ordinary orange juice are good for the health ... reporting studies describing the range of genes that are affected ...
Cached Medicine News:Health News:BET Networks Airs Special Coverage of President Obama's News Conference on Health Care 2Health News:Stryker Operating Results for Quarter Ended June 30, 2009 2Health News:Stryker Operating Results for Quarter Ended June 30, 2009 3Health News:Stryker Operating Results for Quarter Ended June 30, 2009 4Health News:Stryker Operating Results for Quarter Ended June 30, 2009 5Health News:Stryker Operating Results for Quarter Ended June 30, 2009 6Health News:Stryker Operating Results for Quarter Ended June 30, 2009 7Health News:Stryker Operating Results for Quarter Ended June 30, 2009 8Health News:Stryker Operating Results for Quarter Ended June 30, 2009 9Health News:Stryker Operating Results for Quarter Ended June 30, 2009 10Health News:Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2Health News:Notice Begins Announcing Pendency of a Class Action Regarding MetLife 2Health News:Notice Begins Announcing Pendency of a Class Action Regarding MetLife 3Health News:Studies Show Genetic Activity of Antioxidants 2Health News:Studies Show Genetic Activity of Antioxidants 3
(Date:11/28/2014)... 28, 2014 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... Securities Purchase Agreement with Deerfield Management and certain ... will issue shares of preferred stock to Deerfield ... million upon the satisfaction of certain closing conditions. ...
(Date:11/28/2014)... HK$,000Six months endedChange %  30 September 201430 September 2013Turnover 546,011 , ... , 384,242 , 339,113 , 13.3 ... 41,377 , 49.5 Medical Insurance Administration Service Income ... Medical Devices and Accessories Sales , 94,580 , ... 2,917 , 9,219 , (68.4) Impairment Loss ...
(Date:11/27/2014)... November 27, 2014 Hovione announced ... (IND) Application with the U.S. Food and Drug Administration ... of developing improved drug delivery options for established drugs. ... a novel formulation using a new patented crystalline base ... most widely prescribed oral antibiotics for acne. Currently, there ...
Breaking Medicine Technology:Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Hovione Files its First Investigational New Drug Application With the FDA 2
... Biotica Technology,Limited, a privately-held biotechnology company, announces ... to discover, develop,and commercialise novel erythromycin-based macrolides ... In a three year research collaboration, Biotica ... that are not readily,accessible via conventional medicinal ...
... 9 Anesiva, Inc.,(Nasdaq: ANSV ) ... Administration,(FDA) has approved Anesiva,s supplemental New Drug Application ... the pain associated with blood,draws to include adults. ... previously approved to treat the pain,associated with peripheral ...
Cached Medicine Technology:Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline 2Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication 2
... BioCheck FSH EIA Test is ... a solid phase enzyme-linked immunosorbent ... mouse monoclonal anti-FSH for solid ... sheep anti-alpha FSH in the ...
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... glygoprotein produced by the anterior pituitary gland. Like ... FSH consists of subunits designated as alpha and ... sandwich ELISA method. The samples and diluted anti-FSH-HRP ... Mab to FSH beta subunit. FSH in the ...
... is a glycoprotein hormone secreted by ... LH and TSH, the intact FSH ... of alpha- and beta-subunits. Its production ... hormone (GnRH) from the hypothalamus. GnRH ...
Medicine Products: